Changes of Optical Quality During the Peak of the Covid-19 Pandemic

SARS-CoV-2 Clinical Trial

Official title:

Changes of Optical Quality During the Peak of the Covid-19 Pandemic From November 2022 to January 2023 in China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05882383
• Other study ID #: KY-2023019
• Status: Completed
• Start date: November 25, 2022
• Est. completion date: January 20, 2023

Study information

• Verified date: May 2023
• Source: Tianjin Eye Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

Description:

Participants with healthy corneas admitted to Tianjin Eye Hospital from November 25 to January 20, 2022 were followed up . At the end of the follow-up, the investigators recorded in detail whether the patients had undergone real-time reverse transcriptase polymerase chain reaction (covid-19 RT-PCR tests) testing, testing time and results. The presence of PCR-positive during follow-up is considered to be covid-19 infection; PCR-Negative and no symptoms of infection during the follow-up period are considered not infected; participants with symptoms but no PCR test were excluded from the study.Participants were divided into three groups according to the RT-PCR results and the presence or absence of symptoms of infection during follow-up. pentacam (Pentacam HR, Oculus, Wetzlar, Germany) was performed during follow-up and the results were recorded,and the data was statistically managed and compared.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: January 20, 2023
• Est. primary completion date: January 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 32 Years

Eligibility

Included Criteria

1. Best corrected visual acuity (BCVA) = 20/20;

2. No other eye diseases except myopia and astigmatism;

3. The cornea was transparent, and there was no cloud or pannus;

4. No clinical manifestation of Eye disease or systemic disease;

Exclusion Criteria:

1. corneal disease;

2. ocular trauma;

3. Pregnant and lactating women;

Related Conditions & MeSH terms

• Corneal Wavefront Aberration
• COVID-19
• SARS-CoV-2

Locations

Country	Name	City	State
China	Tianjin Eye Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Eye Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The value of cornea aberration	The value of aberration data from pentacam during follow-up were compared, including coma, spherical aberration, defocus, and astigmatism	1 months
Primary	The value of cornea backscatter	The value of cornea backscatter from pentacam during follow-up were compared, including anterior layer,central layer and posterior	1 months
Primary	The value of cornea thickness	The value of cornea thickness from pentacam during follow-up were compared, includig the thinnest point, apex of the cornea.	1 months